QIAGEN to Market Test That Shows if Prostate Cancer Is Responding to Two Therapies

QIAGEN to Market Test That Shows if Prostate Cancer Is Responding to Two Therapies
QIAGEN will begin marketing a test that Johns Hopkins University developed to detect whether advanced prostate cancer patients are failing to respond to the widely used therapies Zytiga (enzalutamide) and Xtandi (abiraterone). If doctors know that a prostate cancer patient is resistant to the drugs, they can develop a more tailored treatment. The test, called AdnaTest Prostate

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *